ASCO
-
BOT+BAL Treatment in MSS mCRC and Immunologically Cold Tumors: Biomarker Data Shows Survival Stratification
Agenus presented new biomarker data at ASCO, showing botensilimab (BOT) plus balstilimab (BAL) can stratify survival in MSS mCRC and other “cold” tumors. This immunotherapy combination shows promise in overcoming resistance by potentially activating the immune response in tumors that typically don’t respond to current checkpoint inhibitors. The data suggests successful identification of biomarkers that predict patient response, paving the way for personalized treatment strategies beyond colorectal cancer.
-
ASCO 2025: Innovent Presents Phase 1/2 Data for IBI363, a First-in-Class PD-1/IL-2α Bispecific Antibody, in Immunotherapy-Refractory Advanced Melanoma
Innovent Biologics announced positive Phase 1/2 data for IBI363, a PD-1/IL-2α-bias bispecific antibody, at ASCO 2025. The study showed promising results in immunotherapy-resistant acral and mucosal melanoma (“cold tumors”), demonstrating a 23.3% confirmed objective response rate and 14.8 months median overall survival. A Phase 2 registration trial for IBI363 is underway, offering a potential breakthrough for advanced melanoma treatment.
-
Genentech’s Itovebi Extends Survival in HR-Positive Advanced Breast Cancer, New Data Reveal
Genentech announced positive overall survival data from the Phase III INAVO120 study, showing that the Itovebi regimen reduced death risk by over 30% in advanced breast cancer patients with PIK3CA mutations. Compared to palbociclib and fulvestrant alone, this Itovebi combination with palbociclib and fulvestrant significantly improved overall survival. The findings will be presented at the 2025 ASCO meeting.
